Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unidentified

ABSTRACT: Business Model Development for Personalized Medicine Based on Integrated Genome and Clinical Information (KAP200000)

PROVIDER: PRJDB19216 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR621698_1.fastq.gz	Fastqsanger.gz
	DRR621698_2.fastq.gz	Fastqsanger.gz
	DRR621699_1.fastq.gz	Fastqsanger.gz
	DRR621699_2.fastq.gz	Fastqsanger.gz
	DRR621700_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 170

Similar Datasets

unidentified

Project description:Marine animal genome information analysis and utilization-based research (KAP220208)

| PRJDB19274 | ENA

unidentified

Project description:Research based on analysis and utilization of marine aquatic organisms genome information (KAP220236)

| PRJDB19297 | ENA

Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.

Project description:The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information. Therefore, a big data of genome-clinical information is important. To determine the feasibility of the use of tumor’s molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(Response rate,PFS, duration of response and overall survival )of patients with advanced cancer, the investigators are going to take a tumor tissue of patients and process molecular profiling and receive molecular profile directed treatments.

| 2201468 | ecrin-mdr-crc

unidentified

Project description:Development of an integrated analysis system of regulatory networks, pathways, and pharmacogenomics based on large-scale gene signatures (KAP210038)

| PRJDB19232 | ENA

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Project description:Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design and personalized medicine approaches for COVID-19.

2022-02-22 | PXD023175 | Pride

unidentified

Project description:Production and assembly of Omija genome information (KAP220322)

| PRJDB19375 | ENA

Hardiansyah2019 - QSP model of chimeric antigen receptor T-Cell therapy

Project description:This QSP model explains how the mechanism of action connects to the clinical outcomes and, therefore, may serve as an important model-based platform to guide the development and personalized dosing of the CART therapy.

2025-01-15 | MODEL2009230001 | BioModels

unidentified

Project description:Comparative Study on Domestic Skate Species Using Genome Information (KAP220257)

| PRJDB19316 | ENA

unidentified

Project description:Comparative Study on Domestic Skate Species Using Genome Information (KAP220267)

| PRJDB19327 | ENA

unidentified

Project description:Comparative Study on Domestic Skate Species Using Genome Information (KAP220254)

| PRJDB19313 | ENA